

#### **Disclaimer**




# By attending the meeting that includes this presentation, or by reading the presentation materials, you agree to be subject to the following restrictions:

- The information involved in this presentation has been prepared by China Reinsurance (Group) Corporation (the "Company"). No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information contained herein. The Company shall not accept any obligation or liability for any loss caused by this presentation or its content or any content related to this presentation (whether by the negligence of the party or otherwise). The information contained in these presentation materials may be updated, improved, modified, verified, and amended, and may be subject to significant change.
- This presentation is based on current economic, legal, market and other conditions in force. It should be understood that subsequent developments may affect the information contained in this presentation, and the Company is not under any obligation to update, revise or affirm.
- Certain information conveyed in this presentation contains statements that are or may be forward-looking. These statements usually include words like "will", "expect", "foresee", and terms of similar meaning. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. In light of these uncertainties, no one should rely on these forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
- This presentation and the materials contained herein are provided for your reference only and may not be copied or distributed, in whole or in part, to anyone else.

2021 Interim Results China Re

# **Agenda**





**Results Overview** 



**Business Analysis** 



**Outlook** 




## Results Overview Rapid growth of profit with prudent risk management





# Results Overview Rapid growth of profit





<sup>1.</sup> Annualized weighted average return on equity = net profit attributable to equity shareholders of the parent company ÷ balance of weighted average equity × 2

### Results Overview | Optimization in business structure




#### **Solid market position**

China Re entered Fortune Global 500 in 2021, ranking *4th*<sup>1</sup> among global reinsurance companies and maintaining its reinsurance leadership

Gross written premiums of the Group in 1H2021

83,277




2021 Interim Results

<sup>1.</sup> Ranked by operating revenue of 2020 (USD 24,376 million)

<sup>2.</sup> Proportion of overseas P&C reinsurance = gross written premiums of overseas P&C reinsurance and Chaucer business ÷ gross written premiums of P&C reinsurance business (excluding inter-segment eliminations)

## **Results Overview** Investment result outperforming the market






<sup>1.</sup> Annualized total investment yield = total investment income ÷ average of total investment assets as at the beginning and end of the period x 2

<sup>2.</sup> Benchmark = change in CSI 300 Index × 80% + change in Hang Seng Index × 20%. Secondary equity investment excludes high dividend portfolios that aim to obtain dividends when compared with index performance.

## **Results Overview** Prudent risk management



#### Risk management was comprehensively strengthened without new major risk events



<sup>1.</sup> S&P Global Rating certified that China Re Group, China Re P&C, China Re Life and China Re HK have a financial strength rating of A and Stable outlook in 2020. A.M. Best Company certified that China Re Group, China Re P&C, China Re Life, China Continent Insurance and Chaucer Insurance Company have a Best's Financial Strength Rating of A (Excellent) and Stable outlook in 2020.

# Results Overview | Accelerated strategy implementation



### Opportunities from national initiatives were seized to constantly cultivate new business growth



# Construction of national governance system

- Deeply participated in catastrophe pilot projects in 16 provinces, cities and regions across the country, and acted as the chief or sole reinsurer in more than 80% of the projects.
- Completed the development of typhoon catastrophe model 2.0 with expert certification, filling the gap in China and reaching the advanced level internationally.
- Premiums of IDI¹ was 503 million yuan in 1H2021 with a YoY increase of 72.9%; the construction of IDI platforms in Beijing, Shanghai, Hainan, Guangdong and other places was promoted and the platform realized a cumulative premiums of 5,434 million yuan with a total protected area of about 130 million square meters.



# Belt and Road construction

- Promoted the establishment of China Belt and Road Reinsurance Pool and served as the chairman and managing agency, which accumulatively underwrote 12 projects and protected overseas assets of 10.1 billion yuan in total.
- Chaucer launched a Belt and Road Consortium at Lloyd's, which initially underwrites political violence risks. The Consortium was led and managed by Chaucer.
- A total of 32 Belt and Road cooperation memorandums have been signed. The cooperation network has covered 136 countries and regions, providing risk protection of about 350 billion yuan for more than 600 projects.



#### **Healthy China initiative**

- Domestic health reinsurance market share maintained No.1. A new model of integration of commercial insurance and social security was created with "Products + Specific Drugs" and "Specific Drugs + Social Security".
- Provided reinsurance support for local inclusive health insurance plans, covering 41 million people in 85 cities, playing a leading role in the market.
- Participated in the first domestic longterm care insurance pilots, developed insurance products including long-term care and critical illness, etc. Launched the first Greater Bay Area cross-border medical insurance and exclusive critical illness insurance.



# Green development strategy

- Provided reinsurance support for environmental pollution liability insurance schemes in many cities
- Provided nuclear insurance for all domestic nuclear power units of nearly 1 trillion yuan nuclear related assets and over 10,000 frontline workers in nuclear related enterprises
- Independently developed agrometeorological index insurance product research and development platform, providing the industry with 26 innovative product solutions for meteorological indexes and providing risk protection capabilities of more than 400 million yuan

1 IDI: Inherent defects insurance




02

**Business Analysis** 



## **P&C Reinsurance** Decrease of premiums with improvement of profitability






Profitability	
Net profit	YoY growth
<b>2,056</b> million	+194.1%
Annualized weighted average return on equity	YoY growth
<i>15.38%</i>	+9.60 <sub>ppts</sub>

<sup>1.</sup> Inter-segment eliminations are excluded.

### **Domestic P&C Reinsurance**

# Rapid premiums growth of non-auto lines (excl. agro) with stable underwriting result





<sup>1.</sup> Data criteria has been changed from the financial statement criteria of China Re P&C to the management criteria after reinstating affiliated transactions within the segments to reflect the actual operation more realistically.

## Domestic P&C Reinsurance | Optimization in business mix with highlighted advantages of emerging lines



Business mix			Pren	niums growth of major emerg	ing lines
Lines	Proportion	YoY growth			
Non-auto¹	71.2%	+2.5ppts		Chinese interest abroad projects insurance	+97.3%
Of which:				Construction surety bond	+62.1%
Emerging lines <sup>2</sup>	9.3%	+1.5ppts		insurance	
				Short-term health insurance	+60.6%
Type of reinsurance arrangement	Proportion	YoY growth		Inherent defects insurance	+20.4%
Facultative reinsurance <sup>3</sup>	9.3%	+2.1ppts			

Proportion of non-auto lines = reinsurance premiums from non-auto lines of domestic P&C reinsurance ÷ reinsurance premiums from domestic P&C reinsurance

Proportion of emerging lines = reinsurance premiums from emerging lines ÷ reinsurance premiums from non-auto lines of domestic P&C reinsurance

<sup>3.</sup> Proportion of facultative reinsurance = reinsurance premiums from domestic P&C facultative reinsurance ÷ reinsurance premiums from domestic P&C reinsurance

# Overseas P&C Reinsurance<sup>1</sup> Grasping the opportunity of rising rates with different strategies in different business sectors




Gross written premiums	and growth (RMB m)		Business strategy
	Gross written premiums	YoY growth	Chaucer: The hardening market opportunity was seized to further expand quality business so that
Overseas P&C Re in total	9,667	+9.1%	<ul> <li>growth in multiple lines has been achieved.</li> <li>Beijing Platform: Business that was poorly performed and with not-as-expected rate increase</li> </ul>
Of which:			was actively reduced; the opportunity of rising rates was seized to continuously expand business in
Chaucer	7,386	+15.1%	<ul> <li>Singapore Branch: Poorly performing business</li> <li>was actively reduced and business structure has</li> </ul>
Other overseas P&C Re	2,281	-6.6%	been constantly optimized.

Data criteria has been changed from the financial statement criteria of overseas P&C reinsurance and Chaucer platforms to the management criteria after reinstating affiliated transactions within the segments to reflect the actual operation more realistically.

# Overseas P&C Reinsurance<sup>1</sup> Improvement of underwriting result from each business sector






Data criteria has been changed from the financial statement criteria of overseas P&C reinsurance and Chaucer platforms to the management criteria after reinstating affiliated transactions within the segments to reflect the actual operation more realistically.

# **L&H Reinsurance** Rapid growth of profit with a more reasonable business mix








<sup>1.</sup> Premiums data only refer to China Re Life (including China Re HK)

# **L&H Reinsurance**<sup>1</sup> Active adjustment of protection-type business mix with premiums and underwriting result remaining stable






- Active adjustment of existing business: renewal of business with poor benefits was terminated
- Active development of profitable business: reinsurance premiums from mid-class medical insurance increased by 49.1% year on year, and the proportion increased by 10.7 ppts







- Actively promoted development of new critical illness insurance and long-term medical insurance; cultivated new business growth such as long-term care insurance, etc.; business structure has been continuously optimized
- Actively prevented and resolved business risk through experience analysis, product iteration, data co-creation, risk control model development, etc.
- Deeply studied risk control mechanism of long-term medical insurance and further deepened "Data + Risk Prevention and Control<sup>®</sup>

Business data only refer to China Re Life, and protection-type business only refers to the domestic.

Combined ratio is calculated after retrocession excluding business management fee.

2021 Interim Results China Re

### L&H Reinsurance

# Innovation momentum with core competitiveness consolidated



### "Product+" and industry integration



Promoting the integration of insurance products and health industry in terms of services, data, categories and scenarios using specific drugs as pilot projects

# "Products + Specific Drugs" provided one-stop solutions

 In Beijing Inclusive Insurance Plan, insurance liability and drug lists were customized for clients, and specific drugs provided from Boao Hope city, Hainan were first introduced.

# Drug usage data were applied to risk pricing to control risk of cost

 Incidence control was replaced by medical expense control based on drug data insights. New areas such as chronic diseases and cancercarrying policyholders have been explored and the market for the elderly has been expanded, which has formed a product solution.

# Specific drug model was extended to medical devices

 A breast prosthesis product for breast cancer protection and a "fully implantable analgesic pump" product were firstly launched.

# Full cycle of medical service was expanded from single insurance scenario

 Insurance products through "hospital rehabilitation + after-hospital care + long-term care" were developed so that new insurance scenarios were expanded.

#### "Data+"



#### **Industry fundamental research**

 Took the responsibility of industry fundamental research and led the compilation of the industry accident insurance rate table.

#### **Data asset development**


 The transfer of data resources to data assets of the company was promoted to expand data analysis dimensions, understand risk trends, and improve pricing capabilities.

#### Medical insurance data linkage

 Data linkage and co-creation between commercial insurance and social security was promoted in several provinces to expand data sources and improve risk control capabilities.

# Primary P&C Insurance | Decrease in premiums with an increase in business cost







<sup>1.</sup> Calculation of the expense ratio includes the effect of government grants.

# **Primary P&C Insurance**

# Constant growth of non-auto business with optimized business structure








# **Asset Management**

# Actively seizing market opportunities to achieve sound investment performance






<sup>1.</sup> Annualized total investment yield = total investment income ÷ average of total investment assets as at the beginning and end of the period × 2

# **Asset Management**

### Increase in total investment assets with a stable asset allocation structure





<sup>1.</sup> Investment assets = Cash and short-term time deposits + financial assets at fair value through profit or loss + financial assets held under resale agreements + time deposits + available-for-sale financial assets + held-to-maturity investments + properties – financial liabilities at fair value through profit or loss - securities sold under agreements to repurchase.


<sup>2.</sup> Sum of percentages of all asset classes amounts to over 100% due to the subtraction of securities sold under agreements to repurchase from total investment assets. Percentage points in the label are the comparison with data as at 31 December 2020.

<sup>3.</sup> Other investments include investment properties, currency swaps, etc.

# **Asset Management**

# Seizing fixed-income investment allocation opportunities and optimizing equity investment portfolio





- 1. Other fixed-income investments primarily include financial assets held under resale agreements, statutory deposits and reinsurers' share of policy loans and others
- 2. Investment funds include monetary funds and the senior tranche of structured index funds.
- 3. Unlisted equity shares include assets management products, unlisted equity investments and equity investment schemes.
- 4. Percentage points in the label are the comparison with data as at 31 December 2020.





03

Outlook

### **Outlook**





From premiums leap in 13th Fiveyear Plan to value improvement in 14th Five-year Plan, China Re will insist on "profitable development, market benchmarks, risk compliance and digital transformation" and the business principle of "stabilizing growth, optimizing structure, controlling risk and improving profitability" to build a world-class comprehensive reinsurance group with sustainable development capability and core competitiveness!

2021 Interim Results China Re



# **Q&A Session**

# **Appendix** Key financial and operating indicators



RMB m (unless otherwise stated)	Jan-Jun 2021	Jan-Jun 2020	Change
Gross written premiums	83,277	102,123	-18.5%
P&C reinsurance	25,403	27,078	-6.2%
L&H reinsurance	35,439	50,500	-29.8%
Primary P&C insurance	23,585	25,763	-8.5%
Net profit	3,977	2,749	44.7%
Net profit attributable to equity shareholders of the parent company	4,011	2,467	62.6%
EPS (RMB)	0.09	0.06	62.6%
Annualized weighted average return on equity <sup>1</sup>	8.50%	5.63%	2.87ppts
Annualized total investment yield <sup>2</sup>	6.55%	5.48%	1.07ppts

<sup>1.</sup> Annualized weighted average return on equity = net profit attributable to equity shareholders of the parent company ÷ balance of weighted average equity × 2

<sup>2.</sup> Annualized total investment yield = total investment income ÷ average of total investment assets as at the beginning and end of the period × 2

# **Appendix** Key financial and operating indicators



RMB m (unless otherwise stated)	30 June 2021	31 December 2020	Change
Total assets	528,327	453,577	16.5%
Total liabilities	424,758	350,676	21.1%
Total equity	103,569	102,901	0.6%
Net assets per share attributable to equity shareholders of the parent company (RMB)	2.21	2.19	0.9%
Core solvency adequacy ratio	172%	189%	-17ppts
Aggregated solvency adequacy ratio	197%	215%	-18ppts
Total investment assets	321,479	307,957	4.4%

2021 Interim Results China Re